Clinical Trials

Phase 1 Not yet recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07353294 2026-01-20

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

12 enrolled

Lymphatic Metastasis

NCT07348107 2026-01-16

ATARI-PDAC

Phase 1 Not yet recruiting

Tumor-Agnostic

Neoplasm Metastasis

NCT07317609 2026-01-05

Endosurgery-02

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

9 enrolled

Head & Neck

Head and Neck Neoplasms

NCT07059299 2025-12-19

NeoTISLEGA

18 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06349837 2025-12-17

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase 1 Active not recruiting

24 enrolled

Other solid neoplasm

Solid Tumor

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Not yet recruiting

Dermatologic

Skin Neoplasms

NCT07077369 2025-07-22

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

Carcinoma, Hepatocellular

NCT06969612 2025-06-06

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06848465 2025-05-11

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

9 enrolled

Colorectal Neoplasms

NCT05984602 2025-04-15

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT06916494 2025-04-10

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Genitourinary

Muscle Invasive Bladder Cancer

NCT06541639 2025-03-18

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

78 enrolled

Other solid neoplasm

Advanced or Recurrent Solid Tumors

NCT05303090 2025-02-27

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

56 enrolled

Pancreatic Ductal Adenocarcinoma

NCT06741982 2024-12-19

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05533892 2023-12-19

CCGLC-007

30 enrolled

Carcinoma, Hepatocellular

NCT05984342 2023-08-09

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

50 enrolled

Esophageal Squamous Cell Carcinoma

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

27 enrolled

Thoracic

High-Risk Resectable NSCLC

NCT05675462 2023-03-06

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

25 enrolled

Carcinoma, Hepatocellular

NCT03287427 2023-02-15

MYPHISMO

27 enrolled

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Colorectal Neoplasms

NCT05659628 2022-12-21

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy